What is Zacks Research’s Estimate for FMS Q4 Earnings?

Fresenius Medical Care AG (NYSE:FMS) – Analysts at Zacks Research increased their Q4 2026 earnings per share (EPS) estimates for Fresenius Medical Care in a research note issued on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $0.62 per share for the quarter, up from their previous forecast of $0.61. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share.

Several other brokerages have also recently weighed in on FMS. Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Truist Financial raised their price target on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, StockNews.com started coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They set a “strong-buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Fresenius Medical Care currently has an average rating of “Hold” and an average price target of $24.30.

Fresenius Medical Care Stock Down 0.3 %

FMS opened at $22.64 on Thursday. Fresenius Medical Care has a 12 month low of $17.93 and a 12 month high of $24.31. The company has a market cap of $13.29 billion, a PE ratio of 18.71, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a 50 day moving average of $22.19 and a 200 day moving average of $20.63.

Institutional Trading of Fresenius Medical Care

A number of institutional investors have recently made changes to their positions in FMS. Allworth Financial LP lifted its holdings in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Fresenius Medical Care in the third quarter worth $38,000. GAMMA Investing LLC boosted its holdings in Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after acquiring an additional 1,675 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Fresenius Medical Care during the 3rd quarter valued at $112,000. Finally, Venturi Wealth Management LLC raised its holdings in Fresenius Medical Care by 1,045.8% in the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after purchasing an additional 4,800 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.